Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

FORT WAYNE, Ind., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Vera Bradley (NASDAQ: VRA) (the "Company”) today announced the appointment of Andrew Meslow, former CEO of L Brands and Bath and Body Works, to the ...

Tempest Therapeutics (TPST) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD, to amezalpat, ...

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds ...

For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study May Proceed” letter from the FDA. From “Boy Meets World” actress Danielle ...

The stock options will vest over a four-ye Company welcomes additional late-stage expertise as it prepares for amezalpat pivotal studyBRISBANE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The US Food and Drug Administration has granted orphan drug designation (ODD) to Tempest Therapeutics' oral, selective peroxisome proliferator-activated receptor alpha (PPAR-α) antagonist amezalpat ...

Tempest Therapeutics, Inc. announced that the FDA has granted Orphan Drug Designation to amezalpat (TPST-1120), a selective PPAR⍺ antagonist, for treating hepatocellular carcinoma (HCC), which ...

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics ...